PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
18.83
Similar to AVXL's ratio of 19.86. Walter Schloss would see both operating with a similar safety margin.
18.83
Similar ratio to AVXL's 19.86. Walter Schloss might see both running close to industry norms.
18.52
Similar ratio to AVXL's 19.00. Walter Schloss would see both following standard liquidity practices.
No Data
No Data available this quarter, please select a different quarter.
89.77
Short-term coverage of 89.77 while AVXL has zero coverage. Bruce Berkowitz would examine if our cash flow management provides advantages.